Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges

B-cell non-Hodgkin lymphoma (NHL) is the most frequent hematologic malignancy. Despite the refinement of chemoimmunotherapy, a substantial number of patients experience chemorefractory disease. Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is considered the most promising and effective th...

Descripción completa

Detalles Bibliográficos
Autores principales: Makita, Shinichi, Imaizumi, Katsuaki, Kurosawa, Saiko, Tobinai, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385623/
https://www.ncbi.nlm.nih.gov/pubmed/30815024
http://dx.doi.org/10.7573/dic.212567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385623/
https://www.ncbi.nlm.nih.gov/pubmed/30815024
http://dx.doi.org/10.7573/dic.212567

Ejemplares similares